ArticlePLoS pathogens2020
The endosymbiont Wolbachia rebounds following antibiotic treatment.
Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis.PLoS neglected tropical diseases · 2026Trial
- Genomics and reproductive biology of Leptopilina malgretoutensis (sp. nov.): an asexual parasitoid of Caribbean Drosophila.Genetics · 2026Article
- Coevolution and Functional Effects of EndosymbioticEcology and evolution · 2026Article
- Cappable-Seq reveals the transcriptional landscape of stress responses in the bacterial endosymbiontMicrobial genomics · 2025Article
- Fexinidazole and Corallopyronin A target Wolbachia-infected sheath cells present in filarial nematodes.PLoS pathogens · 2025Article
- Overcoming limitations to customize DeepVariant for domesticated animals with TrioTrain.Genome research · 2025Article
- Fexinidazole and Corallopyronin A targetbioRxiv : the preprint server for biology · 2025Article
- Overcoming Limitations to Deep Learning in Domesticated Animals with TrioTrain.bioRxiv : the preprint server for biology · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- The cellular lives of Wolbachia.Nature reviews. Microbiology · 2023Review
- Bacterial Community Survey ofInternational journal of molecular sciences · 2023Article
- Aspartyl Protease Inhibitors as Anti-Filarial Drugs.Pathogens (Basel, Switzerland) · 2022Article
- Selective Elimination of Wolbachia from the Leafhopper Yamatotettix flavovittatus Matsumura.Current microbiology · 2022Article
- Pyrvinium Pamoate and Structural Analogs Are Early Macrofilaricide Leads.Pharmaceuticals (Basel, Switzerland) · 2022Article
- High-content approaches to anthelmintic drug screening.Trends in parasitology · 2021Review
- The Eagle effect in the Wolbachia-worm symbiosis.Parasites & vectors · 2021Article
- Transcriptomic Analysis Reveals the Sexually Divergent Host-Microorganisms · 2021Article
- Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases.Pathogens (Basel, Switzerland) · 2021Article
- Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections.PLoS neglected tropical diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
Antibiotic treatment has emerged as a promising strategy to sterilize and kill filarial nematodes due to their dependence on their endosymbiotic bacteria, Wolbachia. Several studies have shown that novel and FDA-approved antibiotics are efficacious at depleting the filarial nematodes of their endosymbiont, thus reducing female fecundity. However, it remains unclear if antibiotics can permanently deplete Wolbachia and cause sterility for the lifespan of the adult worms. Concerns about resistance arising from mass drug administration necessitate a careful exploration of potential Wolbachia recrudescence. In the present study, we investigated the long-term effects of the FDA-approved antibiotic, rifampicin, in the Brugia pahangi jird model of infection. Initially, rifampicin treatment depleted Wolbachia in adult worms and simultaneously impaired female worm fecundity. However, during an 8-month washout period, Wolbachia titers rebounded and embryogenesis returned to normal. Genome sequence analyses of Wolbachia revealed that despite the population bottleneck and recovery, no genetic changes occurred that could account for the rebound. Clusters of densely packed Wolbachia within the worm's ovarian tissues were observed by confocal microscopy and remained in worms treated with rifampicin, suggesting that they may serve as privileged sites that allow Wolbachia to persist in worms while treated with antibiotic. To our knowledge, these clusters have not been previously described and may be the source of the Wolbachia rebound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.